{"id":241941,"date":"2012-05-23T15:11:01","date_gmt":"2012-05-23T15:11:01","guid":{"rendered":"http:\/\/www.eugenesis.com\/psi-announces-new-leadership-in-latin-america\/"},"modified":"2012-05-23T15:11:01","modified_gmt":"2012-05-23T15:11:01","slug":"psi-announces-new-leadership-in-latin-america","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/psi-announces-new-leadership-in-latin-america.php","title":{"rendered":"PSI Announces New Leadership in Latin America"},"content":{"rendered":"<p><p>    ZUG, Switzerland--(BUSINESS WIRE)--  <\/p>\n<p>        PSI CRO, a full service Contract Research Organization,    known for predictable,on-timeenrollment    and     project delivery, announced today that Oscar Podesta has    joined PSI as Head of Latin America. He holds a University    degree in Biochemistry with sixteen years experience in    research, a Fellowship in Clinical Microbiology and further    specialization in Virology.  <\/p>\n<p>    Prior to joining PSI, Mr. Podesta worked in the clinical    research business field, working as a manager for central    laboratory services and has held positions in Operations and    Strategic Development at international CROs and SMOs in Latin    America that have included clinical start up activities in the    region.  <\/p>\n<p>    We are very pleased to have Oscar join PSI at a time when    we are expanding our operational presence in the region which    is directly driven by a strong interest and demand from our    clients worldwide, said Boris Iossel, Head of Project    Management, The Americas. Oscar brings a wealth of    experience and a clear understanding of specifics of growing a    successful operation and understands the challenges of    conducting high quality clinical studies in Latin America.    Supported by our existing experienced clinical and regulatory    teamat our regional headquarters in Buenos Aires, Oscar    will lead our expansion, oversee opening more of our new    offices and manage the continuing growth of our personnel    across Latin American region.  <\/p>\n<p>    Mr. Podesta has an active role in the clinical research market    in Latin America, with participation in the Chamber of CROs    (Brazil and Argentina) and Committee member of the Drug    Information Association Latin American event. Lastly, Mr.    Podesta is currently responsible for Fundraising and Marketing    for a non-profit organization focused on Ethics and Quality in    Clinical Research in Latin America (FECICLA).  <\/p>\n<p>    Mr. Podesta stated, I am very excited with this    opportunity. PSI has the strengths and resources to expand    their business in the region and I am honored the company has    considered me to lead this process. There is no doubt Latin    America is a fertile ground for a patient recruitment centric    international CRO like PSI.  <\/p>\n<p>    About     PSI CRO AG: PSI is a privately-held,     full-service CRO, operating globally with 1,200 employees    worldwide.Global headquarters are located in Zug,    Switzerland at 113a Baarerstrasse 6300.  <\/p>\n<\/p>\n<p>Excerpt from:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/psi-announces-leadership-latin-america-224300546.html;_ylt=A2KJNTsB_rxPrhEAND7_wgt.\" title=\"PSI Announces New Leadership in Latin America\">PSI Announces New Leadership in Latin America<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> ZUG, Switzerland--(BUSINESS WIRE)-- PSI CRO, a full service Contract Research Organization, known for predictable,on-timeenrollment and project delivery, announced today that Oscar Podesta has joined PSI as Head of Latin America. He holds a University degree in Biochemistry with sixteen years experience in research, a Fellowship in Clinical Microbiology and further specialization in Virology. Prior to joining PSI, Mr.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biochemistry\/psi-announces-new-leadership-in-latin-america.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577469],"tags":[],"class_list":["post-241941","post","type-post","status-publish","format-standard","hentry","category-biochemistry"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/241941"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=241941"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/241941\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=241941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=241941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=241941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}